Working… Menu

Efficacy Study of Relaxation to 12 Weeks Against Placebo in the Overall Care Chronic Pain in Patients With Fibromyalgia (Sophrodol-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01628822
Recruitment Status : Completed
First Posted : June 27, 2012
Last Update Posted : April 28, 2016
Information provided by (Responsible Party):
Centre Hospitalier Universitaire, Amiens

Brief Summary:

The main objective of this protocol is to measure the improvement of the overall situation of patients with diffuse chronic pain or fibromyalgia to 12 weeks by non-drug treatment relaxation.

Secondarily,is to evaluate the evolution of physical variables, psychological and social improvement of the quality of life. To evaluate the evolution of drug consumption

Condition or disease Intervention/treatment Phase
Fibromyalgia Behavioral: Active relaxation Behavioral: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Pilot Study, Prospective, Single Center,Randomized, Single Blind, Evaluating the Efficacy of Relaxation to 12 Weeks Against Placebo, in the Overall Care Chronic Pain in Patients With Fibromyalgia
Study Start Date : January 2012
Actual Primary Completion Date : October 2014
Actual Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Active relaxation Behavioral: Active relaxation
The length of follow-up will be 12 weeks.Patients will be seen once every seven days by a relaxation therapist for 5 weeks (6 sessions) and will be followed by the center physician investigator regarding drug therapy

Placebo Comparator: Placebo relaxation Behavioral: Placebo
Patients are been asked to relax alone in a quiet room. They are coming every 7 days for 5 weeks (6 sessions) and will be followed by the investigator regarding drug therapy

Primary Outcome Measures :
  1. scores on Fibromyalgia Impact Questionnaire (FIQ) [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men or women over 18 years
  • established diagnosis of fibromyalgia as defined by the American College of Rheumatology: widespread pain and eleven tender points at 18 sites listed (ACR, 1990)
  • EVA ≥ 4 (on a scale of 10 cm)
  • no change in treatment for 15 days, except for treatment "on demand" or "rescue"
  • patient has given its written consent
  • patient wishing to benefit from relaxation sessions
  • people who can meet the self-assessment and hetero-assessment
  • people with a social security number

Exclusion Criteria:

  • any painful situation that cannot be distinguished from fibromyalgia pain by the patient
  • patients untreated or treated for less than a month
  • patient with psychosis or severe depression or severe anxiety or impulsivity characterized, at the discretion of the clinician.
  • patients receiving benzodiazepines at the request
  • patient with deafness
  • patient after a body treatment using a relaxation method, relaxation therapy or hypnosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01628822

Layout table for location information
Activity Centre "Pain"
Amiens, France, 80054
Sponsors and Collaborators
Centre Hospitalier Universitaire, Amiens
Layout table for investigator information
Principal Investigator: SERRA Eric, Dr Activity Centre "Pain", University Hospital of Amiens
Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire, Amiens Identifier: NCT01628822    
Other Study ID Numbers: AOL11-DR-SERRA
2011-A01055-36 ( Other Identifier: ID-RCB )
First Posted: June 27, 2012    Key Record Dates
Last Update Posted: April 28, 2016
Last Verified: April 2016
Keywords provided by Centre Hospitalier Universitaire, Amiens:
Improving the quality of life
Additional relevant MeSH terms:
Layout table for MeSH terms
Myofascial Pain Syndromes
Chronic Pain
Neurologic Manifestations
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases